8 Knots Management LLC purchased a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,838,011 shares of the company's stock, valued at approximately $8,106,000. GoodRx accounts for 1.0% of 8 Knots Management LLC's investment portfolio, making the stock its 16th biggest holding. 8 Knots Management LLC owned about 0.48% of GoodRx as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of the business. Cubist Systematic Strategies LLC grew its holdings in shares of GoodRx by 146.6% during the 1st quarter. Cubist Systematic Strategies LLC now owns 375,648 shares of the company's stock worth $1,657,000 after purchasing an additional 223,336 shares during the period. Caption Management LLC acquired a new stake in GoodRx in the 1st quarter valued at about $208,000. State of Wyoming raised its position in GoodRx by 76.9% in the 1st quarter. State of Wyoming now owns 119,033 shares of the company's stock valued at $525,000 after purchasing an additional 51,743 shares in the last quarter. EVR Research LP increased its holdings in shares of GoodRx by 243.3% in the 1st quarter. EVR Research LP now owns 1,300,000 shares of the company's stock valued at $5,733,000 after acquiring an additional 921,337 shares during the last quarter. Finally, Walleye Capital LLC increased its holdings in shares of GoodRx by 358.4% in the 1st quarter. Walleye Capital LLC now owns 136,105 shares of the company's stock valued at $600,000 after acquiring an additional 106,412 shares during the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.
GoodRx Stock Performance
Shares of GDRX stock traded down $0.28 during midday trading on Friday, hitting $4.00. The company had a trading volume of 5,761,644 shares, compared to its average volume of 5,752,710. The company's 50 day simple moving average is $4.51 and its 200 day simple moving average is $4.46. GoodRx Holdings, Inc. has a 52-week low of $3.31 and a 52-week high of $8.06. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 40.00, a PEG ratio of 1.86 and a beta of 1.23. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21.
GoodRx (NASDAQ:GDRX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company had revenue of $203.07 million during the quarter, compared to analysts' expectations of $205.72 million. During the same quarter last year, the business posted $0.08 earnings per share. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. Research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on GDRX. The Goldman Sachs Group dropped their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. Raymond James Financial downgraded GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Finally, UBS Group dropped their price target on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, GoodRx currently has a consensus rating of "Hold" and a consensus target price of $5.80.
Get Our Latest Research Report on GDRX
Insider Activity at GoodRx
In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.53% of the stock is owned by corporate insiders.
GoodRx Company Profile
(
Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Further Reading
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
